Company intelligence / Profile preview

Vizzhy

Austin, Texas, United States

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Vizzhy has launched what it describes as the world’s first full-stack metabolic signature program and an AI-powered digital platform for reversing type 2 diabetes, focusing on early detection, prevention, and personalized treatment. Comprehensive clinical results are not publicly summarized, but the company claims its platform enables significant improvements in metabolic health by integrating genomics, metabolomics, microbiome analysis, and biomarker tracking through AI[1][4].

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Digital health platformMulti-omics analysisAI/ML-driven personalized careClinical decision support system
Industry: Digital Health Medical Devices

Partnerships

University of PittsburghIlluminaL&T-CloudfinitiLTIMindtreeAWSNVIDIAThermo Fisher Scientific

Beyond the preview

Go deeper on Vizzhy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vizzhy.

Explore the full profile